Analysts Lowered Abivax Price Targets After Earnings

Financial analysts adjusted expectations following the company's report of greater-than-anticipated losses.

Updated on Sept. 22, 2026 in Corporate Finance

Bold flat-color editorial illustration of a metallic balance weight on a stone surface, representing financial market recalibration.
Analysts at Wedbush and Truist Securities lowered their price targets for Abivax following a first-half earnings report that showed higher-than-expected losses. AI Illustration. Upload story photo >

Live Poll

Do analysts' revised price targets make now a good time to invest in stocks?

Abivax shares declined 0.1 percent to $103.41 in pre-market trading on September 22, 2026. The shift followed the company's first-half earnings report, which revealed losses exceeding analyst consensus estimates.

Why it matters

Investors often recalibrate positions when a company's financial performance deviates from analyst projections. These adjustments reflect broader market sensitivity to corporate earnings reports and operating losses.

Abivax reported a loss of $2.43 per share against an analyst consensus of $1.08. Sales reached $2.959 million, outperforming the consensus estimate of $1.860 million.

The players

Abivax

This is a clinical-stage biotechnology company focused on developing therapeutics for inflammatory diseases.

David Nierengarten

He is an equity research analyst at Wedbush Securities who covers the biotechnology sector.

Gregory Renza

He serves as a research analyst at Truist Securities, specializing in biotechnology and healthcare.

The details

Following the earnings announcement, Wedbush analyst David Nierengarten reduced the Abivax price target from $140 to $118. Truist Securities analyst Gregory Renza similarly adjusted his outlook, lowering the target for the NASDAQ-listed shares from $155 to $151.

Timeline

  1. Abivax reported its first-half financial results on September 21, 2026.

  2. Shares traded at $103.41 during pre-market activity on September 22, 2026.

Market Dynamics

The adjustments to Abivax price targets reflect a standard market reaction within the broader 2026 first-half corporate earnings cycle. Analyst revisions of this nature are typical when companies report results that diverge from established consensus figures.

Retail investors holding Abivax shares may face increased volatility following these downward target adjustments. Traders should evaluate how these revised price targets align with their personal risk tolerance and portfolio strategy.

The takeaway

When analysts lower price targets, it serves as a signal for investors to re-examine the company's operational progress versus its financial overhead. Monitoring these target changes helps shareholders understand how professional forecasters view the long-term potential of their holdings.

Further reading

For broader market updates, visit the Corporate Finance section.

Source note: This article includes information reported by Benzinga.

Live Poll

Do analysts' revised price targets make now a good time to invest in stocks?